Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux 1.5 mg for venous thromboembolism prevention in hospitalized medical patients with renal insufficiency
2008-005234-79Phase 4Completed
- Sponsor
- University of Insubria
- Start
- Nov 2008
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fondaparinux in venous thromboembolism (VTE), sponsored by University of Insubria. Primary endpoint: Incidence of major bleeding. Started Nov 2008; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2008-005234-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005234-79.